10 research outputs found
White privilege, empathy and alterity in higher education : Teaching about race and racism in the sociology of PE and sport
In this chapter we provide a reflexive account on personal experiences teaching in HE in order to consider the extent to which our status as white HE practitioners reinforces and/or undermines white privilege in HE. As lecturers teaching within the discipline of sociology in physical education (PE) and sport contexts, we question whether our delivery of lectures on race and racism effectively challenges racialised discourses and encourages social action within our field. Despite the fact that the undergraduate programmes we work on incorporate lectures on race and ethnicity as a crucial part of the curriculum, these sessions have rarely been delivered by black and minority ethnic (BME) academics. We therefore consider whether our practice can provide a critical pedagogic voice, or if it simply provides a platform for white academics to unconsciously reinforce the institutional whiteness of HE. In particular, we reflect upon the possibility for white academics to empathise with the racialised social experiences of BME students in our cohorts, and the potential risk that our practice simply offers tokenistic discussion of race which reinforce the current forms of inequality and white privilege, whilst violating the alterity of our students
Effectiveness of the Epley’s maneuver performed in primary care to treat posterior canal benign paroxysmal positional vertigo: study protocol for a randomized controlled trial
Religion as an other(ed) identity within physical education: A scoping review of relevant literature and suggestions for practice and inquiry
What happened to critical pedagogy in physical education? An analysis of key critical work in the field
Using density management diagrams to assess crown fire potential in Pinus pinaster Ait. stands
Inkskinned: Gender and Personality Aspects Affecting Heavy Tattooing—A Moderation Model
Understanding how Age-Related Decline in Testosterone Affects Male Sexual Behavior: Neurosteroids as the Missing Piece
Edoxaban versus warfarin in patients with atrial fibrillation
Contains fulltext :
125374.pdf (publisher's version ) (Open Access)BACKGROUND: Edoxaban is a direct oral factor Xa inhibitor with proven antithrombotic effects. The long-term efficacy and safety of edoxaban as compared with warfarin in patients with atrial fibrillation is not known. METHODS: We conducted a randomized, double-blind, double-dummy trial comparing two once-daily regimens of edoxaban with warfarin in 21,105 patients with moderate-to-high-risk atrial fibrillation (median follow-up, 2.8 years). The primary efficacy end point was stroke or systemic embolism. Each edoxaban regimen was tested for noninferiority to warfarin during the treatment period. The principal safety end point was major bleeding. RESULTS: The annualized rate of the primary end point during treatment was 1.50% with warfarin (median time in the therapeutic range, 68.4%), as compared with 1.18% with high-dose edoxaban (hazard ratio, 0.79; 97.5% confidence interval [CI], 0.63 to 0.99; P<0.001 for noninferiority) and 1.61% with low-dose edoxaban (hazard ratio, 1.07; 97.5% CI, 0.87 to 1.31; P=0.005 for noninferiority). In the intention-to-treat analysis, there was a trend favoring high-dose edoxaban versus warfarin (hazard ratio, 0.87; 97.5% CI, 0.73 to 1.04; P=0.08) and an unfavorable trend with low-dose edoxaban versus warfarin (hazard ratio, 1.13; 97.5% CI, 0.96 to 1.34; P=0.10). The annualized rate of major bleeding was 3.43% with warfarin versus 2.75% with high-dose edoxaban (hazard ratio, 0.80; 95% CI, 0.71 to 0.91; P<0.001) and 1.61% with low-dose edoxaban (hazard ratio, 0.47; 95% CI, 0.41 to 0.55; P<0.001). The corresponding annualized rates of death from cardiovascular causes were 3.17% versus 2.74% (hazard ratio, 0.86; 95% CI, 0.77 to 0.97; P=0.01), and 2.71% (hazard ratio, 0.85; 95% CI, 0.76 to 0.96; P=0.008), and the corresponding rates of the key secondary end point (a composite of stroke, systemic embolism, or death from cardiovascular causes) were 4.43% versus 3.85% (hazard ratio, 0.87; 95% CI, 0.78 to 0.96; P=0.005), and 4.23% (hazard ratio, 0.95; 95% CI, 0.86 to 1.05; P=0.32). CONCLUSIONS: Both once-daily regimens of edoxaban were noninferior to warfarin with respect to the prevention of stroke or systemic embolism and were associated with significantly lower rates of bleeding and death from cardiovascular causes. (Funded by Daiichi Sankyo Pharma Development; ENGAGE AF-TIMI 48 ClinicalTrials.gov number, NCT00781391.)